Search
Now showing items 1-10 of 18
Deriving biomarkers from computed tomography using deep learning
(2022-09-23)
X-ray computed tomography (CT) and magnetic resonance imaging (MRI) are widely used structural neuroimaging modalities. For brain atrophy assessment and volumetric quantification using automated methods, MRI is the preferred ...
Risk factors for dementia. Lifestyle, hormones, neurochemistry, and genetics
(2021-05-12)
Objective: The aim of this thesis was to expand the understanding about the effects of lifestyle factors, indicators of endogenous estrogens, and genetic factors on the risk of dementia and cerebrospinal fluid (CSF) markers ...
Development of MALDI Mass Spectrometry Imaging Methods for Probing Spatial Lipid Biochemistry of Amyloid Plaques in Alzheimer's Disease
(2020-05-18)
Alzheimer’s disease (AD) is the most prevalent cause of neurodegenerative
dementia. Aggregation of amyloid β (Aβ) peptides into extracellular Aβ
plaques is one of the major neuropathological features of AD. However,
Aloysius ...
Tau fragments: role as biomarkers and in the pathogenesis of Alzheimer's disease and other tauopathies
(2019-09-10)
N-123 is part of the physiological tau turnover, the generation of tau N-224 was shown to have clinical relevance, being related to AD; N-224 tau showed significantly higher concentrations in AD CSF compared to control and was related to worsening...
Biochemical markers in dementia - Exploring Swedish registry data and the human proteome
(2019-09-04)
Cerebrospinal fluid (CSF) biomarkers of neurodegenerative diseases have a wide scope of applications in diagnostics, prognosis assessment, disease staging, treatment evaluation and more. In this PhD project we aimed to ...
Mild Cognitive Impairment - concepts, cut-offs, and clinical relevance
(2019-04-25)
Mild cognitive impairment (MCI) is a diagnosis frequently used in dementia research and in memory clinics. MCI is meant to identify patients without dementia, but with cognitive decline beyond what is considered normal, ...
The postsynaptic protein neurogranin: a new item in the Alzheimer’s disease biomarker toolbox
(2019-03-13)
Alzheimer’s disease (AD) is the most common form of dementia affecting more than 50 million people worldwide today and is characterised by progressive cognitive decline. One of the earliest events in AD, which is also ...
Cerebrospinal fluid peptidomics: discovery of endogenous peptides as biomarkers of Alzheimer's disease
(2018-10-02)
Neurodegenerative diseases (NDs), the most prominent example of which is Alzheimer’s disease (AD), has turned out to be among the greatest challenges for modern medicine. Common characteristics of NDs involve the aggregation ...
Subjective cognitive decline in memory clinic patients - characteristics and clinical relevance
(2017-05-12)
Subjective cognitive decline (SCD) refers to concerns – symptoms - regarding one’s
cognitive functioning, in the absence of objective evidence of impairment. SCD has
been described as a possible stage preceding mild ...
The role of microglia in Alzheimer's disease - Investigating mechansims regulating amyloid-β clearance
(2016-05-31)
Alzheimer’s disease (AD) is the most common form of dementia today. The disease is characterized by the presence of amyloid plaques and neurofibrillary tangles in the brain, accompanied by a progressive neurodegeneration ...